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Abstract
The current goal of initial antiretroviral (ARV) therapy is suppression of plasma human
immunodeficiency virus (HIV)-1 RNA levels to below 200 copies per milliliter. A proportion of
HIV-infected patients who initiate antiretroviral therapy in clinical practice or antiretroviral
clinical trials either fail to suppress HIV-1 RNA or have HIV-1 RNA levels rebound on therapy.
Frequently, these patients have sustained CD4 cell counts responses and limited or no clinical
symptoms and, therefore, have potentially limited indications for altering therapy which they may
be tolerating well despite increased viral replication. On the other hand, increased viral replication
on therapy leads to selection of resistance mutations to the antiretroviral agents comprising their
therapy and potentially cross-resistance to other agents in the same class decreasing the likelihood
of response to subsequent antiretroviral therapy. The optimal time to switch antiretroviral therapy
to ensure sustained virologic suppression and prevent clinical events in patients who have rebound
in their HIV-1 RNA, yet are stable, is not known. Randomized clinical trials to compare early
versus delayed switching have been difficult to design and more difficult to enroll. In some
clinical trials, such as the AIDS Clinical Trials Group (ACTG) Study A5095, patients randomized
to initial antiretroviral treatment combinations, who fail to suppress HIV-1 RNA or have a
rebound of HIV-1 RNA on therapy are allowed to switch from the initial ARV regimen to a new
regimen, based on clinician and patient decisions. We delineate a statistical framework to estimate
the effect of early versus late regimen change using data from ACTG A5095 in the context of two-
stage designs.
In causal inference, a large class of doubly robust estimators are derived through semiparametric
theory with applications to missing data problems. This class of estimators is motivated through
geometric arguments and relies on large samples for good performance. By now, several authors
have noted that a doubly robust estimator may be suboptimal when the outcome model is
misspecified even if it is semiparametric efficient when the outcome regression model is correctly
specified. Through auxiliary variables, two-stage designs, and within the contextual backdrop of
our scientific problem and clinical study, we propose improved doubly robust, locally efficient
estimators of a population mean and average causal effect for early versus delayed switching to
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second-line ARV treatment regimens. Our analysis of the ACTG A5095 data further demonstrates
how methods that use auxiliary variables can improve over methods that ignore them. Using the
methods developed here, we conclude that patients who switch within 8 weeks of virologic failure
have better clinical outcomes, on average, than patients who delay switching to a new second-line
ARV regimen after failing on the initial regimen. Ordinary statistical methods fail to find such
differences. This article has online supplementary material.
Keywords
Causal inference; Double robustness; Longitudinal data analysis; Missing data; Rubin causal
model; Semiparametric efficient estimation
1. INTRODUCTION
The most current method for treating human immunodeficiency virus (HIV)-1 infected
patients in clinical practice is through a sequence of antiretroviral (ARV) regimens. After
the initial treatment assignment, the sequential treatment strategy is both adaptive and
reactive as subsequent regimen change always depends on response to current regimen,
medical history, as well as tolerability and toxicity of treatment. In antiretroviral studies and
in clinical practice, patients have historically been given treatment choices to sustain virus
suppression, maximize adherence, and minimize toxicity which will, it is hoped, result in
improved clinical health and long-term survival. In general, patients are encouraged to
switch regimens after (confirmed) virologic failure since increased viral replication on the
same regimen may compromise therapy, promote drug resistance, increase the possibility of
cross-resistance to other agents in the same class, and decrease the likelihood that the patient
responds to subsequent antiretroviral therapy (for current treatment guidelines, see
AIDSinfo, www.aidsinfo.nih.gov/Guidelines). The negative aspects of staying on a failing
regimen are counterbalanced by a patient who may be clinically stable for a prolonged
period of time and tolerating their initial regimen despite low levels of viral replication. A
final layer of complexity follows from the fact that switching therapy is no panacea to
improved intermediate or long-term clinical endpoints. Patient-specific genetic and
environmental factors preclude the existence of a single resolution to a complex disease and,
hence, switching ARV therapies may not reduce toxicity nor improve tolerability and may,
in fact, lead to problems with adherence. Here, our aim is to estimate the expected response
for particular ARV treatment sequences and to compare these sequences using the observed
clinical data.
In the clinic, it is observed that some patients successfully suppress viral load on their initial
ARV regimens while others may fail and switch regimens repeatedly. For those patients
who fail virologically and a regimen switch is recommended, the optimal timing of
antiretroviral therapy switch is not known, especially in the setting of relatively low-level
viremia. Although these sequential treatment strategies have been successfully incorporated
in many clinical studies, direct comparisons between different regimens is challenging due
to patient- and provider-initiated treatment decisions after the initial treatment assignment.
For example, ACTG A5095 was a placebo-controlled randomized clinical trial of three ARV
treatment regimens (See Section 2), but the decision of when to switch off a failing first-line
ARV regimen was left to the patient and his or her primary-care provider as long as plasma
HIV-1 RNA did not exceed 10,000 copies/mL when more decisive action was required.
Decisions to stop, continue, or switch treatments, even in the face of incomplete suppression
of HIV-1RNA replication, often depend on multiple other factors including a patient’s
medical history of ARVs, immunologic and clinical response to those ARVs, or
alternatively the desire to limit resistance emergence. Because the same factors that affect a
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patient’s treatment decision and assignment may subsequently affect patient response, we
have a classic case of confounding. By now, statistical techniques to address confounding
are well known (e.g., Horvitz and Thompson 1952; Cassel, Särndal, and Wretman 1976;
Rosenbaum and Rubin 1983a, 1983b; Rosenbaum and Rubin 1984) and lead naturally to
methods of causal inference (Rubin 1974; Holland 1986; Robins 1986).
The premise of our statistical approach is to view regimen change within the context of an
intended ARV treatment strategy or treatment policy; that is, a sequence of treatment
decisions at fixed or random intervals (e.g., routine clinic visits, benchmarks in disease
progression, or some combination thereof) through the follow-up period. We may
conceptualize the observed A5095 data through two treatment decisions and define the
following ARV regimen strategy accordingly:
Definition 1. (ARV Regimen Change Strategy). An initial ARV regimen “a” followed by a
switch to any second-line ARV regimen at time “s,” if virologic failure on the initial
regimen.
It is important to note Definition 1 does not require that patients fail on initial regimen but
does require that patients switch to second-line regimen if they fail on initial regimen. After
the regimen strategy is defined, the goal is to estimate mean outcome for each (a, s)-
treatment strategy combination and perform treatment comparisons. Our principal argument
is that we can estimate the same intent-to-treat (ITT) population parameters in each of three
study designs of increasing complexity—two simplified hypothetical designs and finally the
observed data—under statistical assumptions of increasing strength. We outline the three
proposed study designs below.
In the ACTG A5095 data, we consider two initial ARV regimens, combined efavirenz-
containing regimens (a1) and the triple nucleoside regimen (a2), and switching from a failing
regimen “early” (s1, within 8 weeks of confirmed virologic failure) and “late” (s2).Without
loss of generality, define the population means as {μjk} ≡ {μjk, j, k = 1, 2} for four possible
strategies with initial ARV regimen aj, j = 1, 2, at time sk, k = 1, 2. Our three study designs
are as follows:
D1 A2 × 2 factorial experiment where patients are assigned to one of four treatment
groups at baseline. Policy assignment is completely independent of patient and
provider input. Parameter estimation and inference is performed under an intent-
to-treat (ITT) principle.
D2 A two-stage randomization trial (Stone et al. 1995; Lunceford, Davidian, and
Tsitatis 2002), whereby patients are randomly assigned to initial ARV regimen
and randomized a second time, to switch ARV regimens earlier or later only
after having already failed on their initial ARV regimen. Each randomization is
made independent of patient characteristics.
D3 The observed ACTG A5095 data where patients are randomly assigned to initial
ARV regimen at baseline and then, if virologic failure, switch to second-line
ARV regimen depending on personal decisions and provider input.
In an ITT paradigm, treatment comparisons are made without regard for the success or
failure of the initial ARV regimen and, therefore, the estimands {Mij} reflect the combined
influences and ARVs and viral load levels. In Design D1, ordinary sample averages are
consistent estimators of the ITT estimands of interest. The second study (D2) is the two-
stage randomized design, whereby patients are only randomized to switch early or late if
they failed on the first regimen. In order to estimate {μjk} in this design, we impose
identifiability conditions on potential outcomes (Lunceford, Davidian, and Tsitatis 2002) as
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described in Section 3.1.2. As in Design D1, patients are not forced to fail on the initial
regimen, but it is assumed that patients who do fail will switch regimens.
The existing literature provides methods for regimen strategy comparisons in Designs D1
and D2, but these studies are difficult to implement in therapeutic HIV studies. This is
because many ARV regimen transitions require direct patient or provider intervention, there
exists no a priori set of treatment rules governing regimen change, and many viremic
patients and their providers are unwilling to leave treatment assignment entirely to chance.
Recently, the ACTG initiated a clinical trial (protocol A5115) where patients were randomly
assigned to new ARV regimen after two confirmed HIV-1 RNA levels > 200 copies/mL
(virologic failure) on the current regimen. Unfortunately, patients did not enroll and the
study failed to reach target enrollment and subsequently closed with insufficient power to
detect significant differences between the two groups (Riddler et al. 2007). The statistical
methods proposed here estimate the ITT estimands {μjk} while adjusting for the selection
bias in how patients were assigned to switch early versus late, if they failed on the initial
ARV regimen. A formal connection from the observed data to the second study requires
additional technical conditions and is outlined in Section 3.3.
Assessing the benefit of delayed or immediate switching from a failing ARV regimen is an
important practical problem in HIV research and has been discussed in the scientific
literature previously. The United Kingdom Collaborative HIV Cohort (2008) estimated
factors associated with cause-specific, hazard rates for time-to-switch. Petersen et al. (2008)
used marginal structural models (cf. Murphy, van der Laan, and Robins 2001, and references
therein) to examine the effect on mortality of delayed switch from a failing highly active
antiretroviral treatment (HAART) regimen. Our analysis is more similar to one considered
by Peterson et al. but differs in a couple of important aspects. Because treatment decisions
proceed over two stages in our setting, the additional notation and bookkeeping associated
with marginal structural models is superfluous in the current article. Moreover, our estimator
is minimum variance in a class of doubly robust estimators while Peterson et al. do not
concern themselves with optimal estimation at this level. Furthermore, although mortality is
an important endpoint, it tends to play a small role in current HIV studies because mortality
rates are so low. For example, in ACTG A5095, only 24 out of 1147 patients (2%) died
during a 5-year follow-up.
Our contribution to the literature is threefold. First, we present a systematic framework for
switching from a failing ARV regimen using two-stage designs. The framework is based on
intent-to-treat population parameters and accommodates the fact that not all patients fail on
the current regimen during the study period; however, we do assume that all patients who
fail virologically on current regimen switch to a new regimen. As noted by earlier authors
(see Murphy, van der Laan, and Robins 2001; Lunceford, Davidian, and Tsitatis 2002),
estimating mean potential outcome on treatment strategies differs from conventional
analyses—for example, comparing switch-early versus switch-late conditioning on those
patients who failed on initial regimen—that do not directly address the scientific question of
interest. Second, we propose a one-step regression approximation to the constrained
maximum likelihood estimator (Tan 2006) to estimate mean outcome on treatment strategies
defined in Definition 1. Our proposal extends Tan’s technique to two-stage designs with
selection bias in the second-stage treatment assignment mechanism and continues a recent
trend to develop new and improved doubly robust estimators (Robins et al. 2007; Tan 2006,
2007; Tsiatis and Davidian 2007) beyond the ordinary doubly-robust class (Robins,
Rotnizky, and Zhao 1994). Third, this is a new and particularly intriguing case study of the
ACTG A5095 data. We show that a conventional analysis (one conditioning on only those
patients with confirmed virologic failure) fails to find any statistically significant differences
between early and late switching. However, using the methodology outlined here, we show
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that for patients on efavirenz-based ARV regimens, regimen changes made within 8 weeks
of confirmed virologic failure on initial ARV regimen are associated with lower HIV-1
RNA levels, higher CD4 cell counts, and spend a larger proportion of the follow-up period
with suppressed viral load levels, on average. Finally, our statistical analysis further
exemplifies the benefit of using auxiliary covariates in practice and doubly robust
estimators, in general. The remainder of the article is organized as follows. We describe the
ACTG A5095 data in Section 2 and our methodological approach in Section 3. A summary
of our analysis is described in Section 4 and discussion follows in Section 5.
2. THE ACTG A5095 DATA
ACTG A5095 was a randomized, multicenter clinical trial designed to compare three
antiretroviral regimens in antiretroviral therapy-naive patients with HIV-1RNAlevels ≥ 400
copies/mL. The three initial regimens were: abacavir (ABC)/ lamivudine (3TC)/ zidovudine
(ZDV), 3TC/ZDV+efavirenz (EFV), and ABC/3TC/ZDV+EFV. The goal of the study was
to suppress and maintain HIV-1 RNA levels < 200 copies/mL. The primary efficacy
endpoint was time to first virologic failure, defined as two subsequent assays with HIV-1
RNA levels ≥ 200 copies/mL at or after study week 16. The study enrolled in 18 months and
followed patients for 120 weeks after the enrollment of the last subjects for a median follow-
up of approximately three years. At an interim review after a median of 32-week follow-up,
82 of 382 patients (21%) in the triple nucleoside reverse-transciptase inhibitor (NRTI) group
versus 85 of 765 patients (11%) in the combined efavirenz-containing groups had
experienced virologic failure; hence, the triple NRTI regimen (ABC/3TC/ZDV) appeared
inferior when compared to the combined efavirenz-containing regimens. Moreover, the
time-to-virologic failure was significantly longer in the combined efavirenz-containing
groups. The Data and Safety Monitoring Board recommended that the triple NRTI group be
discontinued but that follow-up in the remaining two groups continue for the remaining
planned duration of the study. Details of the study results, including the early differences
between the triple NRTI and combined efavirenz-containing groups as well as the full
comparative follow-up of the efavirenz-containing groups, have been reported elsewhere
(Gulick et al. 2004, 2006; Ribaudo et al. 2008).
3. METHODS
In this section, we describe concepts that form the basis of the estimation framework. Due to
space limitations, we state and review the basic building blocks for causal inference but do
not elaborate; appropriate references are provided for relevant topics. Although our concept
builds on a two-stage framework, we are primarily interested in treatment comparisons at
the second stage for a particular efavirenz-containing regimen at the first stage.
Nevertheless, we conceptualize our framework through two-stage randomized designs and
adopt notation similar to that in Lunceford, Davidian, and Tsitatis (2002).
3.1 Causal Model: Notation and Assumptions
3.1.1 Potential Outcome Framework—Throughout this article, we adopt Rubin’s
causal model (1974) and the ideas of potential random variables (Neyman 1923; Rubin
1974).We define the potential outcome, Y (aj, sk), j, k = 1, 2, as the outcome one would
observe if a patient were assigned to an ARV regimen strategy in Definition 1, with initial
ARV regimen aj and regimen switch at time sk, if virologic failure on aj. Our notational
convention will be to let a1 denote the two combined efavirenz-containing groups and a2
denote the triple-nucleoside group, with s1 and s2 denoting early and late switch,
respectively, after virologic failure. We also define the potential random variable R(aj) as the
failure status indicator on the initial ARV regimen aj, j = 1, 2; that is, R(aj) = 1 if a randomly
selected patient from the population fails virologically on initial regimen aj and R(aj) = 0
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otherwise. Hence, the full set of potential random variables for a randomly selected patient
from the population is
(1)
3.1.2 Identifiability and Consistency—A noteworthy step in the development below is
an identifiability constraint on the potential outcomes Y (aj, s1) and Y (aj, s2) when virologic
failure is unobserved. In particular, we assume that potential outcomes for patients who do
not fail on initial ARV treatment would be the same whether they were assigned to a
treatment strategy s1 or s2 for early or late switch, respectively, and that potential virologic
failure R(aj) is a function of the initial ARV regimen only and not on a patient’s assigned
switching time (Lunceford, Davidian, and Tsitatis 2002). Hence, we assume that the
distribution of {R(aj), Y(aj, s1), Y(aj, s2)} obeys the constraint
(2)
In ACTG A5095, one does not observe the full set of potential random variables in (1),
rather one only observes the initial ARV regimen, switching time if virologic failure, and the
clinical endpoint. First, we let A denote the initial ARV regimen which realizes two values,
a1 and a2.Next, we define the observed indicator of virologic failure, R, which realizes the
value 1 if a patient failed virologically on initial ARV regimen and 0 otherwise. As in
Lunceford, Davidian, and Tsitatis (2002), we assume that the potential random variables,
R(a1) and R(a2), satisfy the relation R = 1(A = a1)R(a1) + 1(A = a2)R(a2). We let S denote a
dichotomous random variable for switching early (s1) versus late (s2) and is only observed
for those patients who failed on the initial ARV regimen. The observed outcome is Y and
the random vector X denotes patient characteristics. Furthermore, we assume that potential
outcomes Y (aj, sk) and observed outcome Y are related through
(3)
Incidentally, because we assume Equation (2), then we also have that conditional on the
event {A = aj}, Y = (1 − R)Y (aj, s2) + R1(S = s1)Y (aj, s1) + R1(S = s2)Y (aj, s2). In contrast
to the potential random variables given in (1), the observed random variables are {A, R, RS,
Y, X}.
3.1.3 Treatment Assignment—In ACTG A5095, eligible patients were randomly
assigned to initial ARV treatment stratified according to their viral load level at screening.
Hence, because of randomization, treatment assignment is independent of specific patient
characteristics within each stratum, that is, P(A = aj | Y (aj, s1), Y(aj, s2), X) = P(A = aj).
Similarly, it is necessary to consider how patients are assigned to switch ARVs early versus
late postvirologic failure. Here, patients were not assigned to treatment independent of
individual characteristics; rather patients and their attending physicians intentionally chose
to switch early or late on a case-by-case basis. Hence, we have P(S = sk | R = 1, Y(aj, s1),
Y(aj, s2), X) ≠ P(S = sk | R = 1). However, we do assume that
(4)
Expression (4) is often referred to as the no unmeasured confounders assumption or
sequential randomization. We interpret Equation (4) as the assumption that a decision to
switch early versus late depends on auxiliary variables X up to that point at which a switch
is made but unrelated to future events Y (aj, s1) and Y (aj, s2).
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3.2 Estimation in a Hypothetical, Randomized Two-Stage Trial (D2)
To motivate our estimator in Section 3.3 using data from the observational study, we first
consider estimation in a hypothetical two-stage randomization trial where treatment
assignment to switch early or late is independent of patient characteristics. For clarity, we let
Ed̄2 and Pd̄2 denote expectation and probability in the hypothetical two-stage trial,
respectively. In the hypothetical randomized study, there are no confounding variables X
and the observed data are simply {A, R, RS, Y}. This hypothetical trial is exactly the
scenario considered by Lunceford, Davidian, and Tsitatis (2002) where expression (4), with
no X, holds easily as a consequence of randomization. Using conditioning arguments via
Equations (2) and (3), Lunceford, Davidian, and Tsitatis (2002) show that for each (aj, sk)
combination, the causal estimand μjk is related to the observed data in a two-stage
randomized design through
(5)
Replacing Ed̄2 with the sample average of the random variables on the right-hand side of
Equation (5) leads to a consistent and asymptotically normal estimator for the estimand μjk
under an ITT principle, Equations (2) and (3), and known propensitites. The interpretation of
the weighting scheme in Equation (5) is as follows: if a patient does not fail on the initial
ARV regimen aj, then that patient represents him/herself and hence receives a weight of 1; if
a patient fails on initial ARV regimen, however, then that patient represents {Pd̄2 (S = sk | A
= aj, R = 1)}−1 similar patients who could have potentially been assigned to combined
sequential first- and second-line ARV regimens (aj, sk). In the following section, we show
how to extend the expression (5) for the analysis of the ACTG A5095 data.
3.3 Estimation in the Observational Study (D3)
We use results provided by Murphy, van der Laan, and Robins (2001) to derive a consistent
estimator of μjk using the observed data from the ACTG A5095 study. Under regularity
conditions, including P(S = sk | A = aj, R = 1, X) > 0, Lemma 4.1 of Murphy, van der Laan,
and Robins (2001) asserts that the distribution of (Y, A, R, S) under Pd̄2 is absolutely
continuous with respect to the distribution of (Y, A, R, S) under P, and a version of the
Radon–Nikodym derivative is E{Wd̄2 (A, R, S, X) | Y = y, A = a, R = r, S = s}, where
The Radon–Nikodym derivative can be applied directly to the expression in Equation (5) to
show that
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The last expression in Equation (6) is a function of the observed data {Y, A, R, RS, X} and
a sample average yields a consistent estimator for μjk if the propensity score P(S = sk | A =
aj, R = 1, X) were known.
By definition, the propensity score P(S = sk | A = aj, R = 1, X) is estimable only by those
patients who failed on their initial ARV regimen and not by the entire sample. Hence, in
small samples, estimation and inference for the causal estimand μjk may be sensitive to the
overall marginal probability of failing on initial ARV regimen. Nevertheless, the propensity
score may be modeled parametrically, semiparametrically, or nonparametrically as a
function of (A, X). The most common approach is to model P(S = sk | A = aj, R = 1, X)
using maximum likelihood via generalized linear models (e.g., probit or logistic regression)
and separately for each initial ARV regimen aj. Substituting the fitted propensity score P̂(S =
sk | A = aj, R = 1, X) in expression (6) and taking a sample average leads to a standard
inverse-probability weighted (IPW) estimator
where ℰn denotes sample average (i.e., . Assuming that the propensity
model is correctly specified and under standard regularity conditions, 
converges in distribution to a mean-zero normal random variable with asymptotic variance
that can be derived using standard arguments (e.g., Tsiatis 2006) and consistently estimated
from the data (e.g., Lunceford, Davidian, and Tsitatis 2002; Tsiatis 2006).
3.4 Doubly Robust, Locally Efficient, and Optimal Estimation
Semiparametric efficient estimation and double robustness in missing data problems has
been an active research area for two decades now following the work of Robins, Rotnizky,
and Zhao (1994). The doubly robust estimators of Robins, Rotnizky, and Zhao (1994) are
attractive because they provide some robustness to model misspecification and can achieve
the semiparametric efficiency bounds when all modeling assumptions are correct. At the
same time, several authors have noted that the same estimator can behave poorly in finite
samples when one or both modeling assumptions are incorrect. We review and extend these
estimators to our analysis of the ACTG A5095 data.
For the purposes of robust and efficient estimation, we drop the indicator 1(A = aj) from our
description with the understanding that estimators are computed separately for each initial
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ARV regimen; here, we focus on the efavirenz-containing regimens. We define the switch
indicator
the propensity score P(Z = 1 | R = 1, X) = P(S = s1 | R = 1, X) = π(X), which is modeled via
logistic regression,
(7)
where ψ = (ψ0, …, ψq−1)T is a q-vector of regression coefficients for 11 potential
confounders (see Section 4). Then the inverse-probability weighted (IPW) estimator for an
ARV regimen strategy (that switches early) is simply
(8)
(9)
The analogous IPW estimator for “switch late” to second-line ARV regimen is given by
replacing Z/π̂(X) in Equation (8) with (1 − Z)/{1 − π̂(X)}. Next, we show how to construct
improved semiparametric estimators by minimizing asymptotic variance.
By applying the theory of Robins, Rotnizky, and Zhao (1994), we know that all regular and
asymptotically linear (RAL) estimators μ̂ of μ take the form
(10)
where h(·) is an arbitrary function of X. In the missing data literature, the last expression
R{Z/π(X, ψ) − 1}h(X) in Equation (10) is called the augmentation term (Tsiatis 2006).We
note that the class of influence functions for μ̂ is {(10) − μ} and the IPW influence function
is one that simply has h ≡ 0. The semiparametric efficient estimator is found when h(X) =
−m(X), with m(X) = E(Y | R = 1, X). Because the true conditional mean model E(Y | R = 1,
X) is unknown, we posit a statistical model for it, say E(Y | R = 1, X; ξ) = m(X, ξ). Here,
we model the conditional mean of Y given X for patients who failed on initial ARV regimen
linearly as
(11)
where ξ = (ξ0, ξ1, …, ξr−1)T is an r-vector of unknown parameters for covariables including
baseline CD4 cell counts and HIV-1 RNA level at virologic failure. Then, replacing h(X)
with the posited model m(X, ξ) leads to an augmented inverse-probability weighted (AIPW)
class of estimators:
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We know that the AIPW estimator is consistent if either π(X) or m(X) is correctly specified
(i.e., double robustness; Robins, Rotnizky, and Zhao 1994; Tsiatis 2006), and the AIPW
estimator is semiparametric efficient if π(X) and m(X) are both correctly specified (i.e.,
local efficiency). Unfortunately, if the conditional mean model m(X) is incorrectly specified,
there is no promise that the AIPW estimator is optimal in any sense. Hence, the AIPW
estimator class will not include the efficient estimator if m(X) is misspecified even though it
does include the efficient estimator when m(X) is correctly specified. These considerations
lead to other families of estimators which may be motivated through different
considerations.
Noting that the AIPW estimator could be less efficient than the IPW estimator if the
conditional mean model m(X) is misspecified, the authors (Robins et al. 1995) considered an
adaptive estimator which is guaranteed to be more efficient than the IPW estimator. Here,
Robins et al. restricts to the class of estimators whose influence functions are of the form
(12)
which leads to the class of estimators in Equation (10) when h(X) = ξTX. Then, the goal is
to find the estimator in the restricted class given in Equation (12) whose variance is
minimum. One can show that the estimator with minimum variance in the class defined by
Equation (12) is
where κ̂ serves as the first element to the classic multiple linear regression
{ℰn(VVT)}−1ℰn(V U), U = RZY/π(X, ψ̂), V = R(Z/π(X, ψ̂) − 1) × G, and
In the two-stage design framework, we note that μ̂RRZ is similar to the Wahed and Tsiatis
(2004) estimator if κ̂ in G is replaced by G∗ = (1, m(X, ξ̂))T. The estimator μ̂RRZ or that
proposed by Wahed and Tsiatis (2004) in two-stage designs is no longer consistent if π(X)
is incorrectly modeled in Equation (7).
Recently, Tan (2006) proposed estimators that are motivated from a theory of control
variates and constrained maximum likelihood. Tan’s preferred estimator (the so-called
“tilde” or “regression” estimator) has the same minimum variance property as the estimator
proposed by Robins et al. (1995). However, Tan’s estimator is doubly-robust while the
estimator by Robins et al. (1995) is not (Tan 2007, Proposition 4). Specifically, the
appropriate extension of Tan’s estimator to our particular application is
where κ̂ is a scalar defined as the first element of {ℰn(VWT)}−1ℰn(V U), W = R(Z/π(X, ψ̂))
× G, and V, U, and G were defined earlier. The form of Tan’s regression estimator is
analogous to that proposed by Robins et al. (1995) although it is motivated as a first-order
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approximation to a restricted maximum likelihood estimator. Both μ̂REG and μ̂RRZ are
consistent if π(X) is correctly modeled but μ̂REG has minimum variance. If both π(X) and
m(X) are correctly modeled, the differences between the two estimators are asymptotically
negligible. Details for estimating the asymptotic variance of μ̂REG and μ̂RRZ are provided in
the Appendix.
4. ANALYSIS OF THE ACTG A5095 DATA
4.1 The Study Sample
A total of 1147 subjects enrolled in the ACTG A5095 between March 2001 and November
2002. Of the original 1147 patients, 12 patients never started their initial treatments. These
12 patients were removed from our analysis as indicated later.
As mentioned briefly in Section 2, the Data Safety and Monitoring Board recommended that
the triple-nucleoside group be discontinued at the second annual review in February 2003
and study investigators followed this recommendation. For ease of exposition, our analysis
is therefore restricted to the two combined efavirenz-containing groups (Gulick et al. 2004,
2006). In addition, we excluded 14 patients who did experience virologic failure, are not
observed to switch therapy, and are not followed for at least 8 weeks since virologic failure.
Thus, our effective sample size is 744 patients on the two combined efavirenz-containing
groups, where 137 (18.4% of 744) patients experienced virologic failure on their initial ARV
treatment regimens. An additional 45 (6.0% of 744) patients experienced virologic failure
but only after a protocol-approved drug substitution in the same drug class for treatment-
limiting drug-related toxicity (e.g., stavudine for zidovudine, nevirapine for efavirenz).
Hence, they were not following their initial randomized ARV at the time of failure but they
were following our working definition of “initial ARV regimen” (see also, Section 4.4).
We quantitatively describe our study sample in Table 1 through a summary of baseline
characteristics. Patient age ranges from 18 to 77 years old; weight has a mean of 76 kg with
standard deviation of 16 kg. Sex is an indicator variable (1 if male); race is a three-level
variable (0 if white, 1 if black, and 2 for any other race); drug history indicates whether a
patient ever previously used intravenous (IV) drugs, (1 if ever an IV drug user and 0
otherwise). Baseline HIV-1 RNA and HIV-1 RNA level at virologic failure are presented on
the logarithmic scale; baseline CD4 cell counts, baseline CD8 cell counts, and time (in
weeks) from baseline to first virologic failure remain their original scales.
4.2 Treatment and Endpoint Definitions
The results of our analyses depend critically on the definitions of virologic failure (R),
switching off a failing regimen early versus late (S), and the endpoint (Y). Our definition of
confirmed virologic failure follows one defined in theACTGA5095 protocol: lab readings
from two consecutive visits where HIV-1 RNA ≥ 200 copies/mL after at least 16 weeks of
study treatment. We define “failure” as “confirmed virologic failure on the first-line
treatment regimen” and first-line regimen to include initial ARV regimen plus any protocol-
approved drug substitutions. Our definitions for “early” versus “late” ARV regimen switch
and three different outcomes are described in the paragraphs that follow.
Our preferred definition for switching ARV regimens “early” was switching regimens less
than 8 weeks after confirmed virologic failure. In Figure 1, we see that the proportion of
patients switching ARV regimen less than 8 weeks was 17.0% (31 of 182) patients in the
combined efavirenz-containing group. We considered other cutoffs to define early switch,
including 12, 16, and 20 weeks. We chose 8 weeks to define early switch because it agrees
with provider’s experience in the clinic and, per the A5095 study design, was equivalent to
the clinic visit following the visit at which a confirmatory HIV-1 RNA level above 200
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copies/mL was measured (i.e., two clinic visits after the date of virologic failure). We also
considered a four-week cutoff but so few patients met the criteria that we did not pursue it
further.
In two-stage analyses, the endpoint Y must be well-defined for all treatment combinations.
Perhaps the most natural endpoint is death or time-to-death (cf. Petersen et al. 2008) but
mortality is seldom considered a primary endpoint in most HIV studies due to the successes
of ARV regimens. Also, because some HIV studies do not extend beyond two to three years
of follow-up, few HIV-related deaths are actually observed. In A5095, for example, only 24
patients died during five years of follow-up. In the sequel, we use length-adjusted area-
under-the-curve (AUC) endpoints. Cumulative viral load, cumulative CD4 cell count, or
equivalently their AUC counterparts, are sensitive to ARV regimens and valuable
scientifically (Fleming 1994; Journot et al. 2001; Fletcher et al. 2008; Marconi et al. 2011;
Torti et al. 2011). Cumulative viral load is associated with and often used as an early
indicator of virologic failure (cf. Fleming 1994; Journot et al. 2001; Marconi et al. 2011).We
used AUC endpoints in our statistical analysis because they are relevant clinically and well-
defined for all patients on a particular ARV regimen strategy, including those patients that
did not fail their initial regimen.
Let H(t) be the viral load or CD4 cell count at time t and α(t) a nonnegative weight function.
A patient’s AUC is defined by the Riemann–Stieltjes integral
where L is the patient’s length of follow-up and follow-up is defined as length from the first
viral load drawing date to the off-study date. Our endpoints are defined Y = AUC/L and
interpreted as the length-adjusted AUC (cf. Spritzler, DeGruttola, and Pei 2008), where the
length-adjustment accounts for differences in follow-up time. In practice, the AUC is
approximated through the Riemann sum , where Hj = H(tj) for j = 1, …, J and
Δαj = α(tj) − α(tj−1). One conventional definition uses a constant weight α(t) = 1 which
implies Δαj = (tj − tj−1) while the modified definition Δαj = [(tj+1 − tj) + (tj − tj−1)]/2 leads
to the linear trapezoidal rule (Yeh and Kwan 1978); we report results using the latter
definition.
We consider three specific endpoints: (i) H(t) is viral load (HIV-1 RNA in copies/mL) at
time t and α(t) = 1 for all t; (ii) H(t) = 1 and α(t) = 1{HIV-1 RNA (copies/mL) at time t ≤
200}; (iii) H(t) is CD4 cell count at time t with α(t) = 1. The first endpoint is interpreted as
cumulative viral load with large values suggesting higher viral load levels per unit of time,
on average. We interpret the second endpoint “Days below the limit of detection (LOD)” as
the proportion of time with suppressed viral load and the third endpoint is the same as the
first but with CD4 cell count replacing HIV-1 RNA. Length-adjusted AUC of viral load and
CD4 are transformed on a natural logarithmic scale (see also, Section 4.4). The mean and
standard deviation of our endpoints are included as part of our analytic results in Table 4.
We provide additional comments on our endpoints in the online supplementary material.
4.3 Main Analysis
The first step in our statistical analysis is to fit the propensity score (PS) model (7) and the
outcome regression (OR) model (11) for 182 patients with virologic failure. Here, we fit the
PS model using multiple logistic regression with a binary outcome for the time of ARV
regimen change (1 if switched early within 8 weeks after failure and 0 otherwise) and
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covariables including age, weight, race, sex, time from baseline to the first virologic failure,
baseline CD4 cell counts, baseline CD8 cell counts, baseline viral load, and HIV-1 RNA
level at virologic failure, drug history. HIV-1RNAlevel at virologic failure is not included
when the endpoint is adjusted cumulative viral load. Each of the variables (age, weight,
baseline CD4 cell count, baseline CD8 cell count, and time to first failure) are normalized
before entering the models. For the OR models, we fit multiple linear regression models for
each of our three AUC endpoints using the same covariables as in the PS model. The
estimated regression coefficients in the PS and OR models are described in Tables 2 and 3,
respectively.
In Table 2, we found that patients with higher baseline viral load levels are more likely to
switch earlier rather than later. Also, HIV-1 RNA level at virologic failure was strongly
associated with switching early, with higher levels more likely to switch early. The
remaining covariates are not significantly associated with the timing of ARV regimen
change among those who failed on first-line regimen. The outcome regression model results
are presented in Table 3. First, controlled for other covariates, cumulative viral load is
positively associated with baseline viral load level and baseline CD4 cell count; it is
negatively associated with the time to virologic failure among patients that changed
regimens after 8 weeks. Second, HIV-1 RNA level at virologic failure is negatively
associated with the days below the limit of detection. Third, among patients who change
regimens after 8 weeks of confirmed virologic failure, patients with longer time to virologic
failure and lower baseline CD4 cell counts have a higher proportion of days below the limit
of detection during the total follow-up period. Fourth, HIV-1 RNA level at virologic failure
is negatively associated with cumulative CD4 cell counts. Finally, time to virologic failure
and baseline CD4 cell counts are positively associated with cumulative CD4 cell counts
among patients who switch to second-line ARV regimen after 8 weeks.
Table 4 presents the analytic results for three primary endpoints using auxiliary covariates in
Table 1. We include parameter estimates from the following six estimators: the sample
average conditioning on those patients that failed their initial ARV regimen (COND),
inverse-probability weighted (IPW) estimator, the IPW estimator with no auxiliary variables
(IPW no Aux) in the propensity score model, the augmented IPW (AIPW) estimator, the
minimum variance estimator of Robins et al. (1995, RRZ), and the proposed regression
estimator (REG). Note, that an AIPW estimator with no auxiliary covariates in the PS or OR
model is numerically equivalent to the “IPW no Aux” estimator. We conduct formal
hypothesis tests that the average causal effect equals zero, that is, no difference between
regimen strategies that switch early (s = 1) versus late (s = 0). In the case of naive (COND)
estimates, we report the squared two-sample t-test statistic so that it is asymptotically
distributed  under the null hypothesis. Additional details for test statistics reported in
Table 4 are provided in the Appendix.
In Table 4, we first note that the conditional (COND) estimates are quite different than all
other estimates—HIV-1 RNA estimates are substantially larger, days below LOD estimates
shorter, and CD4 estimates are smaller. This observation is because COND is not estimating
the same quantity as the other five estimators. The IPW, IPW no Aux, AIPW, RRZ, and
REG estimators are estimating the mean outcome for a particular ARV regimen strategy
while COND is not. The COND estimator excludes information from all patients who do not
experience virologic failure and so the effective sample size is smaller. The COND
estimator would only be consistent for ARV regimen strategy in Definition 1 if all patients
failed on initial ARV regimen and, additionally in the observed data, the timing of regimen
change did not depend on potential confounders.
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The next comparison is between two IPW estimators, one that models the propensity score
via Table 2 and another (IPW no Aux) that ignores auxiliary covariates altogether. Here, it is
clear that at least one of the auxiliary variables is having an impact on the HIV-1 RNA
endpoint. Upon closer inspection of Tables 2 and 3, we find that baseline HIV-1 RNA,
HIV-1 RNA at virologic failure, and time to virologic failure all appear to play an important
role. At the same time, it appears that adjusting for auxiliary variables in the PS model for
the IPW estimator has minimal impact on the conclusions for the LOD and CD4 endpoints.
The doubly robust estimators (AIPW, RRZ, and REG) take advantage of the auxiliary
variables through the PS and OR model and generally have smaller standard errors than the
corresponding IPW estimators. The AIPW estimate for the HIV-1 RNA endpoint within 8
weeks is almost two units larger than the IPW estimate (183.71 versus 181.88) and the
AIPW standard error estimate is also larger. This leads to a null finding for the HIV-1 RNA
endpoint using AIPW estimates whereas the conclusion using IPW estimates was
significantly different. This is due to fact that the AIPW estimate can be adversely affected
by small samples in the augmentation; this is also reflected by a larger standard error
estimate. However, both the RRZ and REG estimates are similar to the IPW estimates and
all three lead to the same conclusion. For days below LOD and the CD4 endpoints, the
AIPW, RRZ, and REG estimates are all very similar. The RRZ standard error estimate for
early switch in the CD4 endpoint was much larger than AIPW and REG and, therefore, led
to a null finding putting it in disagreement with AIPW and REG.
In general, our results suggest there are significant differences in HIV-1 RNA, days below
the LOD and CD4 cell counts between patients switching early versus late to second-line
ARV regimens in the combined efavirenz-containing groups. In particular, viral load is
generally lower while CD4 cell counts are greater for those patients switching earlier rather
than later. Our findings also suggest that patients who switch within 8 weeks after confirmed
virologic failure spend more days below 200 copies/mL, on average. For example, after one
year of follow-up, patients following a treatment strategy which switched to second-line
regimen within 8 weeks after virologic failure suppressed viral load levels to below 200
copies/mL for an average 296 days (365 × 0.81, 95% CI: 292–300 days), compared to 285
days (365 × 0.78, 95% CI: 281–289 days) for switching to second-line regimen beyond
8weeks after virologic failure. Hence, on average, patients spend about 11 days more with
viral load levels below 200 copies/mL if they switch from a failing ARV regimen within 8
weeks. In conclusion, using our current definitions, we find evidence to suggest switching to
second-line ARV regimen within 8 weeks of confirmed virologic failure from an efavirenz-
containing regimen is associated with modest improvements in virologic and immunologic
endpoints.
4.4 Sensitivity and Secondary Analyses
The sensitivity of our analytic results depend on identifiability assumptions, modeling
assumptions, and may further depend on user-specified definitions and variable
transformations included at any stage of the statistical analysis. Throughout this article, we
work within the ubiquitous causal inference assumptions (3) and (4) and do not dwell on
their veracity. All doubly robust estimators are consistent if either the propensity score
model (7) or the outcome model (11) are correctly specified. If both Equations (7) and (11)
are misspecified, none of the estimators discussed in this article are guaranteed to be
consistent. Nonparametric models could be used instead, for example, but the resulting
estimator would no longer be regular and asymptotically linear. The foci of our additional
analyses are to assess the sensitivity and robustness of our conclusions to alternative
treatment definitions, endpoint definitions, and variable transformations. Our findings are
tersely summarized below but detailed in the online supplementary material.
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The following sensitivity analyses were performed:
• (Subset auxiliary variables) Our main analysis used the same set of baseline
covariables (with the exception of HIV-1 RNA level at virologic failure)
throughout all propensity and outcome models, and for all three endpoints.
Alternatively, we can perform subset selection and retain only significant
confounders. We found that point estimates, standard error estimates, and tests of
signficance changed only modestly.
• (Alternate definition of treatment policy) Our working definition of treatment
strategy allowed all protocol-approved drug substitutions and implied that 45
patients were not actually following their initial randomized treatment at the time
of virologic failure. Alternatively, we could have simply removed these patients
from the analysis or treated them as a separate subgroup. Using the same auxiliary
variables in Tables 2 and 3, we found that most conclusions did not change from
the main analysis in Table 4 for cumulative CD4 cell counts and proportion of time
with suppressed HIV-1 RNA. However, there is no significant difference for
cumulativeHIV-1 RNA between two groups.
• (Alternate definition of endpoint) In Section 4, we computed endpoints calculating
length-adjusted AUC of viral load and CD4 cell counts on their logarithmic scale
(base 10). Alternatively, we could have first computed length-adjusted AUC on the
original scale and then taken up logarithmic transformation. We mainly considered
two different methods for computing the outcome not only because of the observed
long right tail in the AUC empirical distribution but also because our Wald tests are
not invariant to transformation. Nevertheless, all results remained similar except for
one. We saw mild deviation in the magnitude of the difference in point estimates
for the cumulative viral load endpoint compared to those presented in Table 4 but
our tests of significance still rejected the null hypothesis at the nominal level.
Hence, we found that the results reported in Table 4 were generally repeated across the
scenarios considered above. This is not proof that the results are correct but it does suggest
that conclusions are not easily shaken by modest changes in our variable definitions.
5. DISCUSSION
The primary goal of this article was to address a scientific question in therapeutic HIV
research where there is an abundance of conjecture and speculation but limited evidence: is
it better to switch early or late from a failing ARV regimen? The ACTG attempted to answer
this question through a randomized controlled clinical trial but found the trial difficult to
enroll (Riddler et al. 2007). Alternatively, one may perform a secondary analysis on existing
data from another study where assignment to change ARV regimen early or late depends on
patient-specific characteristics. Although standard sample averages and two-sample tests
cannot be used to analyze such data, methods of causal inference may be used and have
become a staple of modern statistical inference. To answer the aforementioned scientific
question using data from ACTG A5095, we built a statistical framework through potential
outcomes (Rubin 1974) and two-stage designs (Lunceford, Davidian, and Tsitatis 2002) and
a consistent IPW estimator for an intent-to-treat estimand using theory from Murphy, van
der Laan, and Robins (2001). Note, that our intent-to-treat estimand is motivated by and
analogous to one that would be estimated if ACTG A5115 (Riddler et al. 2007) had enrolled.
Next, we derived a one-step regression approximation to a constrained maximum likelihood
estimator (Tan 2006) for this problem and applied it to the A5095 data. Using this
combination of techniques, we found that patients who started a standard combination
antiretroviral regimen of nucleoside analogs and efavirenz and then employed the strategy to
make regimen changes within 8 weeks of confirmed virologic failure on initial ARV
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regimen had lower cumulative viral load levels, higher cumulative CD4 cell counts, and
spent a larger proportion of the follow-up period with suppressed viral load levels, on
average. Although no definitive conclusions can be drawn from this secondary analysis, our
results do suggest that switching earlier rather than later from a failing ARV regimen was
associated with virologic and immunologic benefits.
It is difficult to say for certain whether the average differences in HIV-1 RNA, days below a
limit of detection, or CD4 cell count reported in Table 4 are clinically relevant or not. In
general, clinically significant differences in HIV-1 RNA and CD4 are discussed as patient-
specific changes: < 0.5 log10 change in HIV-1 RNA (copies/mL) are not considered
clinically significant and, for CD4 cell count, a 30% change in absolute count or 3% change
is deemed clinically significant (AETC National Resource Center, www.aids-ed.org). We
concede that average differences in absolute HIV-1 RNA or CD4 may be difficult to
translate to the clinical experience and a patient-specific relative measure would have been
preferable. However, endpoints defined as functions of a limit of detection are reputable
and, historically, have been used in defining primary endpoints for numerous clinical studies
including ACTG A5095 (Gulick et al. 2004, 2006). When we began this project several
years ago, our scientific objective was to identify treatment strategies that lead to sustained,
low levels of HIV-1 RNA below the limit of detection. While this endpoint could not be
defined through the available data, we did conceive of another endpoint, “time below the
limit of detection,” that could be defined through the observations. In our analysis, we found
that patients who switched to second-line ARV regimen within 8 weeks of confirmed
virologic failure had viral load levels suppressed below the limit of detection for 11 days
more, on average, than patients who delayed switching. In general, lower levels of viremia
are indicative of less development of drug resistance, slowed disease progression, and
positive response to therapy. Hence, while it is difficult to say whether 11 days of reduced
viremia leads to definitive improved clinical benefits, it is reported that viral load reductions
of less than 0.5 log copies or less are associated with clinical benefits (Murray et al. 1999).
TheACTGA5095 study is an example of a clinical trial whose primary objective was to test
the efficacy of initial regimens but we used it in a secondary analysis of regimen change. If
ACTG A5115 is any indication of the future, it will be difficult to design and enroll a
completely randomized study of regimen change. In this case, data like that from ACTG
A5095 and the framework employed here will be germane for evaluating the effect of early
regimen change. As with many clinical studies, however, there are often caveats that make
secondary analyses tricky. A limitation of our analysis is that patients who switched to
second-line regimen within 8 weeks of initial virologic failure may have more follow-up
data post-second-line treatment than do patients who delay switching. We attempted to
adjust for the discrepancy by adjusting for length of follow-up but it would have been
preferable to measure and analyze an endpoint that was exogenous to the timing of the
second-line ARV treatment decision. One response to this potential criticism is that it is not
evident, based on the literature or the clinical experience of the coauthors, whether more
follow-up necessarily leads to better or worse outcomes and such assumption was one of our
working hypotheses when we started this project. A second response to this potential
criticism is to increase the sample size from a larger clinical study at the outset or to
combine several smaller studies.
In addition to additional analyses listed in Section 4.4, we also considered different
thresholds for an early versus delayed regimen change. The decision to define switching
early as switching within 8 weeks after failing on the first-line regimen was made by
investigators in the ACTG A5095 team and physicians who actually participated in the
study. Nevertheless, we tried different thresholds including 90, 120, and 150 days. In
general, we found that significance differences between early and late regimen change
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disappeared as timing of the threshold increases. Other methods that do not require
dichotomizing the time of regimen change are desirable but we conjecture would not make a
significant impact in the current analysis due to limited numbers of patients who actually
changed regimens within several months of confirmed virologic failure.
For some statistical hypotheses within the combined efavirenz-containing group, it may be
necessary to account for early stoppage of the triple-nucleoside group. To further elucidate
this point, suppose that one had designed a study (analogous to D1 in Section 1) to test
early-versus-late regimen change for two treatment groups, perhaps with the null hypothesis
of no early-versus-late difference in either treatment group. If one treatment a2 was stopped
early and we proceeded to perform early-versus-late comparisons on treatment a1 that
continued, then these treatment comparisons might be biased and the tests of significance
may have the incorrect size. In this case, it would be prudent to consider group sequential
methods (cf. Pocock 1977; Tsiatis, Rosner, and Mehta 1984; Emerson 2006) to account for
the sequential monitoring that led to the premature discontinuation treatment a2. In the
analysis of the ACTG A5095 data in Section 4, we were primarily concerned with correcting
bias due to confounding and robust estimation of mean outcome for a particular treatment
strategy defined through Definition 1. Additional statistical issues introduced by sequential
monitoring could be an extension of our methods in Section 3 and may be an interesting
avenue for future research, but it was beyond the scope of the current article.
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APPENDIX
STANDARD ERROR ESTIMATION AND HYPOTHESIS TESTING
Under standard regularity conditions, our estimator behaves asymptotically as if the
parameter κ j, j = 0, 1 were known a priori and defined in Section 3.3.3. For completeness,
we define the whole system of estimating equations, 0 = ℰnϕθ (Z, θ), where
, and,
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Standard arguments lead to the usual sandwich formula for the asymptotic covariance of θ̂
and a consistent estimator given by Σ̂θ = Â−1B̂(Â−1)T. The asymptotic covariance estimator
for μ = (μ1,μ0)T, i.e., , is the upper right 2 × 2 matrix of Σ̂θ.
A consistent estimator for the average causal effect (ACE) for switching ARV regimens
early versus late is given by δ̂ = μ̂1 − μ̂0. Our Wald test statistic for the difference between
early vs. late switch shows T = (Cμ)T(CΣμCT)−1(Cμ), where C = (1, −1), is asymptotically
distributed as  under the null hypothesis of no difference.
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Number of patients at each stage. “Switch early” is defined as switching to second-line
regimen less than 8 weeks after confirmed virologic failure.
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Table 1









Baseline HIV-1 RNA    4.86 (0.73)     5.29 (0.70)     4.81 (0.69)
HIV-1 RNA at virologic failure   3.74†(0.94)     4.17 (0.90)     3.65 (0.92)
Time to virologic failure 55.46†(37.45)   57.08 (39.49)   55.12 (37.15)
Baseline CD4 cell count 241.39 (192.54) 183.05 (165.21) 260.06 (211.52)
Baseline CD8 cell count 846.65 (509.31) 882.61 (598.55) 850.68 (603.72)
Body weight   76.22 (16.21)   70.97 (14.15)   75.25 (14.59)
Age   37.46 (9.26)   38.16 (8.88)   37.33 (9.35)
Sex   80.78   80.65   82.12
Drug history   10.62   19.35   13.91
Race
    White   41.27   29.03   37.09
    Black   35.08   41.94   43.04
    Hispanic or others   23.65   29.03   19.87
†
Descriptive statistics for HIV-1 RNA at virologic failure and time to virologic failure pertain only to 182 patients who experienced virologic
failure.
NOTE: Baseline HIV-1 RNA (copies/mL) and HIV-1 RNA (copies/mL) are transformed on a base-10 logarithmic scale, time to first failure is
measured in days, body weight in kilograms, age at baseline (age) in years, gender (sex) is reported as proportion male, and drug history is
proportion who have ever used intravenous drugs.
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Table 2
Coefficient estimates from propensity score model P(Z = 1|R = 1,X) for switching within 8 weeks of






Intercept −8.20 (2.21) −6.64 (2.01)
Baseline HIV-1 RNA   0.80 (0.38)   0.89 (0.37)
HIV-1 RNA at virologic failure   0.54 (0.23)       —
Time to virologic failure   0.15 (0.22)   0.09 (0.22)
Baseline CD4 cell count −0.18 (0.32) −0.12 (0.30)
Baseline CD8 cell count   0.02 (0.18)   0.09 (0.18)
Body weight −0.18 (0.28) −0.23 (0.28)
Age   0.02 (0.22)   0.05 (0.21)
Sex   0.15 (0.62)   0.18 (0.60)
Drug history   0.50 (0.58)   0.39 (0.56)
Race
    White       —       —
    Black   0.29 (0.54)   0.37 (0.52)
    Hispanic or other   0.50 (0.62)   0.67 (0.59)
NOTE: Propensity model 2 is used when the endpoint is HIV-1 RNA and model 1 is used otherwise.
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